Using natriuretic peptides to screen for, identify and treat stage B heart failure in people with type 2 diabetes: An initial cost‐effectiveness analysis

Documenti analoghi

• Discontinuation of SGLT2i in people with type 2 diabetes following hospitalisation for heart failure: A cause for concern?
  di: Tamara Y. Milder, et al.
  Pubblicazione: (2024)
• Disparities in heart failure deaths among people with diabetes in the United States: 1999–2020
  di: Benjamin Grobman, et al.
  Pubblicazione: (2025)
• Mortality risk following ischaemic and non‐ischaemic heart failure in people with type 2 diabetes: Observational study in England, 2000–2021
  di: Kajal Panchal, et al.
  Pubblicazione: (2025)
• Follow‐up and monitoring programme in children identified in early‐stage type 1 diabetes during screening in the general population of Italy
  di: Valentino Cherubini, et al.
  Pubblicazione: (2024)
• Sodium–glucose cotransporter 2 inhibitors reduce the risk of incident type 2 diabetes in people with heart failure without diabetes: An analysis of real‐world, cohort data
  di: Alex E. Henney, et al.
  Pubblicazione: (2024)